M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors
- Journal
- ACS Nano
In The Last Decade
doi.org/10.1021/acsnano.8b02446 →Countries where authors are citing M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors
This map shows the geographic impact of M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors more than expected).
Fields of papers citing M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors
This network shows the impact of M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
About M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors
This paper, published in 2018, received 381 indexed citations . Written by Yeon Woong Choo, Mikyung Kang, Han Young Kim, Jin Han, Seokyung Kang, Ju‐Ro Lee, Gun‐Jae Jeong, Sung Pil Kwon, Seuk Young Song and Seokhyeong Go covering the research area of Immunology and Molecular Biology. It is primarily cited by scholars working on Molecular Biology (244 citations), Immunology (184 citations) and Biomedical Engineering (161 citations). Published in ACS Nano.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1021/acsnano.8b02446.